Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6899774 | 0.83 | TSHR (0.39) | — | |
| SCHEMBL2679479 | 0.82 | HTT (0.47) | — | |
| SCHEMBL10898329 | 0.80 | — | — | |
| SCHEMBL4735789 | 0.79 | — | — | |
| SCHEMBL6894897 | 0.79 | CTSK (0.30) | — | |
| SCHEMBL6894582 | 0.79 | — | — | |
| SCHEMBL304413 | 0.79 | — | — | |
| SCHEMBL16399093 | 0.78 | DGAT1 (0.32) | — | |
| SCHEMBL2980874 | 0.78 | MAPT (0.34) | — | |
| SCHEMBL2981105 | 0.78 | MAPT (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553989-B2 | Malonic acid monoesters and process for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-30 | — | — | US | disclosed |
| US-20050272950-A1 | Malonic acid monoesters and process for producing the same | MEIJI SEIKA KAISHA LTD. (JP) | 2005-12-08 | — | — | US | disclosed |
| EP-1561748-A1 | MALONIC ACID MONOESTERS AND PROCESS FOR PRODUCING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2005-08-10 | — | — | EP | disclosed |
| US-4755598-A | 1'-(substituted)ethyl-7β-[2-(2-aminothiazol-4-yl)acetamido]-3-[[[1-(2-dimethylaminoethyl)-1H-tetrazol-5-yl]thio]methyl]ceph-3-em-4-carboxylate derivatives having antibacterial utility | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-07-05 | — | — | US | disclosed |
| US-4612143-A | Process for the preparation of fluoroformates | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1986-09-16 | — | — | US | disclosed |
| EP-0128028-A2 | Cephalosporin derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1984-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272950-A1 | Malonic acid monoesters and process for producing the same | ME1, SI, ME3 | GRIN2D 4490/4885GRIN3B 3897/4885GRIN1 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.